Reversible dual inhibitor against G9a and DNMT1 improves human iPSC derivation enhancing MET and facilitating transcription factor engagement to the genome

• Juan Roberto Rodriguez-Madoz ,

  Roles Conceptualization, Formal analysis, Funding acquisition, Supervision, Writing – original draft, Writing – review & editing

  * E-mail: fprosper@unav.es (FP); jrrodriguez@unav.es (JRRM)

  Affiliation Cell Therapy Program, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain

  http://orcid.org/0000-0003-4327-1866

  ⨯
• Edurne San Jose-Eneriz,

  Roles Investigation

  Affiliation Oncohematology Program, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain

  ⨯
• Obdulia Rabal,

  Roles Investigation, Resources

  Affiliation Small Molecule Discovery Platform, Molecular Therapeutics Program, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain

  ⨯
• Natalia Zapata-Linares,

  Roles Investigation

  Current address: Centre de Recherché Saint-Antoine, UMR_S938, INSERM/UPMC, Paris, France.

  Affiliation Cell Therapy Program, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain

  ⨯
• Estibaliz Miranda,

  Roles Investigation

  Affiliation Oncohematology Program, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain

  ⨯
• Saray Rodriguez,

  Roles Investigation

  Affiliation Cell Therapy Program, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain

  ⨯
• Angelo Porciuncula,

  Roles Investigation

  Current address: Dysautonomia Center, New York University School of Medicine, New York, NY, United States of America.

  Affiliation Cell Therapy Program, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain

  ⨯
• Amaia Vilas-Zornoza,

  Roles Investigation

  Affiliation Oncohematology Program, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain

  ⨯
• Leire Garate,

  Roles Investigation

  Affiliation Oncohematology Program, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain

  ⨯
• Victor Segura,

  Roles Formal analysis

  Affiliation Bioinformatics Unit, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain

  ⨯
• Elizabeth Guruceaga,

  Roles Formal analysis

  Affiliation Bioinformatics Unit, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain

  ⨯
• Xabier Agirre,

  Roles Conceptualization, Funding acquisition, Writing – review & editing

  Affiliation Oncohematology Program, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain

  ⨯
• Julen Oyarzabal,

  Roles Conceptualization, Writing – review & editing

  Affiliation Small Molecule Discovery Platform, Molecular Therapeutics Program, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain

  ⨯
• Felipe Prosper

  Roles Conceptualization, Funding acquisition, Writing – original draft, Writing – review & editing

  * E-mail: fprosper@unav.es (FP); jrrodriguez@unav.es (JRRM)

  Affiliations Cell Therapy Program, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain, Oncohematology Program, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain, Hematology and Area of Cell Therapy, Clínica Universidad de Navarra, University of Navarra, Pamplona, Spain

  ⨯